1 / 15

Chronic Liver Diseases Therapeutics Market

Read here the market research report published by CMI team.

PriyaCmi
Télécharger la présentation

Chronic Liver Diseases Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

  2. CHRONIC LIVER DISEASES THERAPEUTICS MARKET ANALYSIS • Chronic Liver Diseases Therapeutics Market, by Therapy Type (Anti-Rejection Drugs/Immunosuppressant’s, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Immunoglobulins, and Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

  3. The global chronic liver diseases therapeutics market is expected to witness significant growth during the forecast period owing to the increasing prevalence of liver disease. As the main reason causing cirrhosis is high consumption of alcohol. For instance, in 2015, according to the National Survey on Drug Use and Health (NSDUH) data, around 88,000 people (around 62,000 men and 26,000 women) died due to alcohol-related causes annually, which makes alcohol consumption the fourth leading preventable cause of death in the U.S. • Similarly, the high number of patients with chronic liver disease such as cirrhosis is contributing to the growth of the global chronic liver disease therapeutic market. • Global Chronic Liver Diseases Therapeutics Market - Impact of Coronavirus (Covid-19) Pandemic • The spread of coronavirus has negatively impacted the global chronic liver disease therapeutics market. The outbreak of this virus has hindered the growth of the global market. The U.S has the highest number of corona patients which is expected to impact the country’s economic condition. The U.S is high potential market for the pharmaceuticals industry, and the economic slowdown of the U.S economy is likely to impact the market for pharmaceutical drugs

  4. Similarly, markets in India, Brazil, Russia and other economies are also suffering due to Covid-19 attack that is expected to impact on lowering the pharmaceutical growth.  Furthermore, due to COVID-19 pandemic, hospitals are closed in containment zones, that has slowed the hospital visits and stabilized the demand for therapeutic drugs of chronic liver diseases. • The global chronic liver diseases therapeutics market is estimated to be valued at US$ 12.8 Bn in 2020 and is expected to exhibit a CAGR of 9.7% during the forecast period (2020-2027).

  5. Figure 1. Global Chronic Liver Diseases Therapeutics Market Share (%) Analysis in 2020, By Therapy Type

  6. Global Chronic Liver Diseases Therapeutics Market - Restraints • Side effects and risks associated with liver disease therapeutics are expected to hinder growth of the global liver disease therapeutics market. The side effects associated with the use of liver therapeutics are nausea, headache, fever loss of appetite, and drug-induced liver disease. Moreover, availability of alternate treatment procedures such as organ transplantation and liver resection are also expected to limit growth of the market.

  7. Market Opportunities • Increasing research and development of immunotoxins is expected to offer lucrative growth opportunities to players operating in the global chronic liver disease therapeutics market. For instance, GPC3 is a cell surface heparansulfate proteoglycan that is overexpressed in hepatocellular carcinoma. Anti-GPC3 immunotoxins can be effective in the treatment of human hepatocellular carcinoma. • Moreover, clinical trials of new therapies are also expected to aid the market growth. For instance, in March 2018, the U.S. FDA granted Orphan Drug Designation for Protagonist Therapeutics, Inc.’s PTG-300; a subcutaneous injectable in clinical development stage for the potential treatment of beta-thalassemia and liver fibrosis

  8. Figure 2. Global Chronic Liver Diseases Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027

  9. Global Chronic Liver Diseases Therapeutics Market – Regional Analysis • On the basis of region, the global chronic liver disease therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. • The market in North America is expected to witness significant growth owing to presence of major players in the region. Players are focused on collaboration strategies to expand their product portfolio. For instance, in April 2020, Alnylam Pharmaceuticals, Inc. collaborated with Dicerna Pharmaceuticals, Inc. for development and commercialization of investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease.

  10. Global Chronic Liver Diseases Therapeutics Market - Competitive Landscape • Key players operating in the global chronic liver disease therapeutics market are AstellasPharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.

  11. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • Buy Now Referencehttps://www.coherentmarketinsights.com/market-insight/chronic-liver-diseases-therapeutics-market-4047

  12. About Us Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  13. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  14. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related